400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR-OIC-17010625
结束
/
/
/
2017-02-02
/
/
退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
先導計劃 - 研究富血小板血漿注射治療退化性膝關節炎
研究富血小板血漿注射治療退化性膝關節炎
单臂
Ⅱ期
NA
/
NA
/
12
/
1990-01-01
1990-01-01
/
1) Aged 45 to 75 years old; 2) Self-reported symptoms consistent with KOA per American College of Rheumatology guidelines; 3) Have experienced moderate to severe knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question "What is the average level of your left/right knee pain?" 4) Failed 6 months of usual care; 5) Clinical evidence of KOA according to the American College of Rheumatology guidelines; 6) Radiographic evidence of KOA with Kellgren Lawerance (KL).;
请登录查看1) Pregnancy; 2) On anticoagulation, immunosuppressive or daily opioid therapy; 3) History of collagen tissue or other autoimmune disorders; 4) Hematological diseases; 5) Severe cardiovascular diseases; 6) Prior or planned total knee replacement of the affected knee; 7) Allergy or intolerance to acetaminophen or xylocaine; 8) Body mass index (BMI) ≥ 35 kg/m2; 9) Co-morbidity severe enough to prevent reliable or safe study participation; 10) Subjects who cannot read or write in the Chinese Consent form; 11) Interim knee joint infectious arthritis or trauma; 12) Hemoglobin level < 11g/dL; 13) Platelet concentration < 150,000/mm3; 14) Clinical examination suggesting that the patient is not appropriate due to comorbid knee or other conditions.;
请登录查看The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
/
皮肤好医荟2025-12-04
体外诊断原料网2025-12-04
优赛生命2025-12-04
医药时间2025-12-04
佰傲谷BioValley2025-12-04
求实药社2025-12-04
启迪之星2025-12-04
亚虹医药2025-12-04
幂方健康基金2025-12-04
汉氏联合2025-12-04